1888. TB-HIV: Major Advances in Evidence-based Treatment Recommendations
Session: Pre-meeting Session: TB Workshop $
Wednesday, October 2, 2013: 10:00 AM
Room: The Moscone Center: 270-276
Diane Havlir, MD, FIDSA, University of California at San Francisco, San Francisco, CA

Dr. Havlir is Professor of Medicine at UCSF and Chief of the HIV/AIDS Division at San Francisco General Hospital. She was a physician in training at UCSF when the AIDS epidemic emerged in the 1980s and has cared for HIV-infected patients for over 25 years. She is an active researcher who has published over 150 articles and who pioneered some of the first studies of HIV antiretroviral therapy and drugs to prevent AIDS complications. Her recent efforts showed that prompt initiation of antiretroviral therapy in patient with HIV and tuberculosis can significantly reduce mortality and AIDS. She is principal investigator for the ACTG unit at UCSF and the PROMOTE program project which is studying HIV and malaria therapeutic strategies. She founded the SEARCH collaboration which is evaluating medical, economic and education outcomes of universal HIV therapy through a streamlined delivery approach in East Africa. Dr. Havlir has played an active role on the global stage as one of the authors and architects of the first WHO Global HIV treatment guidelines. In concert, she helped establish a global HIV drug resistance surveillance program. She is a member of the Board of the STOP TB partnership and chair of the HIV and TB working group. She served on the Governing Council for the International AIDS Society and is an advisor to the Infectious Disease Center for Global Health Policy. She has won numerous awards including the HIV Medical Association Research Award and the AIDS Research Institute Mentorship Award. She was elected to the American Society for Clinical Investigation. Dr. Havlir was Co-chair of the International AIDS Conference in Washington DC in July, 2012.

See more of: TB Workshop $
See more of: Pre-meeting Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.